Sign InSummary
T2 Biosystems, Inc. (TTOO) experienced a significant surge in stock price on July 10, 2023, but long-term bearish trends, financial instability, and the company's small size indicate potential uncertainties and risks for investors, classifying it as a 'Hold' until more consistent financials are observed.
Introduction
T2 Biosystems, Inc. (TTOO) is a company listed on the NASDAQ exchange. T2 Biosystems is engaged in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
Price Performance
As of July 10, 2023, TTOO last closed at a price of $0.16. The stock witnessed a sizable surge of 37.39% on the same day, which was undoubtedly a significant increment. The daily low and high prices were $0.14 and $0.17 respectively. The annual high for TTOO was $15, demonstrating that the current price is substantially lower from the year high, suggestive of potential headwinds for the business. Meanwhile, the stock's annual low is $0.05, with the current price considerably higher.
Market Performance and Liquidity
T2 Biosystems has a market capitalization of $3.93 million, making it a small-cap stock. The trading volume on the last trading day was 241.46 million, significantly above its average volume of 35.58 million, which indicates a high level of public engagement and liquidity of the stock. The large volume also suggests significant interest in the company's latest developments.
Technical Indicators
The 50-day moving average of TTOO is $0.16, which is slightly above its current price. This may suggest that the stock is in a short-term bearish trend. The 200-day moving average is $1.29, which is substantially more than the current rate. This suggests a long-term bearish trend. The RSI stands at 81, which is generally considered overbought, and may suggest potential downward price adjustment. The stock's MACD for the last three months is negative at -0.01, further reflecting a bearish sentiment.
Financial Performance
The EPS of TTOO stands at -$14.39, and the PE ratio is negative which indicates that the company is facing profitability issues. A negative EPS suggests financial strain and may dampen investor confidence.
Recent News and Developments
Several significant announcements could be impacting the TTOO stock's movement. On June 6, the company highlighted that it had submitted an application for a Breakthrough Device Designation for its Candida auris test to the FDA. This development could underline the company's commitment to innovation and lead to significant benefits if the application is approved. On June 1, the company announced new sales of instruments in Poland, which could serve as an additional revenue stream.
Conclusion
Looking onto July 11, 2023, while technical analysis suggests a potentially bearish sentiment in the short term owing to the RSI and MACD, interest in the stock, as demonstrated by the high trading volume, may bolster the price.
For the upcoming week, considering the company's recent developments and substantial increase in the stock price, there could be continued interest from the market, at least in the short term.
Despite these positive developments and the short-term interest of the market, the company's long-term bearish trend, its current financial instability and the small size of the company leave a lot of uncertainties. Therefore, a potential investor should clearly understand the risks versus rewards in this case.
Final Evaluation
Based on the information and developments, the stock of T2 Biosystems, Inc. appears to require more stabilization and fundamental improvement for a firm recommendation. Therefore, TTOO can be classified presently as a 'Hold' until more consistent financials are observed. With any investment, it is crucial to do proper research and due diligence. The high-risk nature of this penny stock should not be ignored, and potential investors should be conscious of this risk when making their decision.
